8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Mar 25, 2026·SEC
Material company update
Jan 8, 2026·SEC
KalVista Pharmaceuticals, Inc.(KALV)Earnings, Financials & Key Ratios
KALV•NASDAQ
Price updated Jun 19, 2026
AboutKalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.Show more
- Revenue$74M
- EBITDA-$170M+8.9%
- Net Income-$164M+10.4%
- EPS (Diluted)-3.23+12.5%
- Gross Margin91.75%
- EBITDA Margin-231.45%
- Operating Margin-233.42%
- Net Margin-223.16%
- ROE-354.52%-191.8%
KALV Key Insights
KalVista Pharmaceuticals, Inc. (KALV) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 94 (top 6%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Profits declining 28.9% over 5 years
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when KALV posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
KALV Price & Volume
KalVista Pharmaceuticals, Inc. (KALV) stock price & volume — 10-year historical chart
Loading chart...
KALV Growth Metrics
KalVista Pharmaceuticals, Inc. (KALV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years42.49%
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM24.54%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM13.87%
Return on Capital
10 Years-59.75%
5 Years-67.75%
3 Years-78.25%
Last Year-71.06%
KALV Recent Earnings
KalVista Pharmaceuticals, Inc. (KALV) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 1/12 qtrs (17%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.92-144.5%
$0.38
Rev
$14M-64.9%
$39M
Q2 2026
May 7, 2026Metric
Actual
Est
EPS
$0.92-144.5%
$0.38
Rev
$14M-65.0%
$39M
Q2 2026
May 5, 2026Metric
Actual
Est
EPS
$0.92-144.5%
$0.38
Rev
$14M-65.0%
$39M
Q2 2026
Mar 24, 2026Metric
Actual
Est
EPS
$1.01-87.0%
$0.54
Rev
$1M-73.4%
$5M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.92vs $0.38-144.5% | $14Mvs $39M-64.9% |
| Q2 2026 | May 7, 2026 | $0.92vs $0.38-144.5% | $14Mvs $39M-65.0% |
| Q2 2026 | May 5, 2026 | $0.92vs $0.38-144.5% | $14Mvs $39M-65.0% |
| Q2 2026 | Mar 24, 2026 | $1.01vs $0.54-87.0% | $1Mvs $5M-73.4% |
Based on last 12 quarters of dataView full earnings history →
KALV Peer Comparison
KalVista Pharmaceuticals, Inc. (KALV) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BDTX | 95.12M | 1.66 | 4.26 | -36.37% | 0.13 | |||
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 KALA | 79.17M | 3.61 | -1.09 | -13.36% | ||||
 XOMA | 525.34M | 41.89 | 28.69 | 83.06% | 86.97% | 30.21% | 1.27 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 ADMA | 1.93B | 8.31 | 13.85 | 19.63% | 32.43% | 38.97% | 0.17 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 ARDX | 1.48B | 6.05 | -23.27 | 22.09% | -13.58% | -38.11% | 1.27 |
Compare KALV vs Peers
KalVista Pharmaceuticals, Inc. (KALV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KALV Income Statement
KalVista Pharmaceuticals, Inc. (KALV) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Apr'18 | Apr'19 | Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | Apr'25 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 8.39M | 16.13M | 12.69M | 0 | 0 | 0 | 0 | 0 | 73.62M |
Revenue Growth % | 458.11% | 92.13% | -21.31% | -100% | - | - | - | - | - |
Cost of Goods Sold | 18.24K | 35.02K | 40.19M | 41.29M | 0 | 0 | 86.17M | 0 | 6.08M |
COGS % of Revenue | 0.22% | 0.22% | 316.74% | - | - | - | - | - | 8.25% |
Gross Profit | 8.38M▲ 0% | 16.09M▲ 92.1% | -27.5M▼ 270.9% | -41.29M▼ 50.1% | 0▲ 100.0% | 0▲ 0% | -86.17M▲ 0% | 0▲ 100.0% | 67.54M▲ 0% |
Gross Margin % | 99.78% | 99.78% | -216.74% | - | - | - | - | - | 91.75% |
Gross Profit Growth % | 461.63% | 92.13% | -270.92% | -50.11% | 100% | - | - | 100% | - |
Operating Expenses | 27.1M | 45.95M | 13.03M | 16.64M | 96.61M | 110.87M | 54.28M | 188M | 239.38M |
OpEx % of Revenue | 322.84% | 284.91% | 102.67% | - | - | - | - | - | 325.17% |
Selling, General & Admin | 8.86M | 10.93M | 13.03M | 16.64M | 26.45M | 30.59M | 54.28M | 116.29M | 183.74M |
SG&A % of Revenue | 105.58% | 67.75% | 102.67% | - | - | - | - | - | 249.59% |
Research & Development | 18.24M | 35.02M | 40.19M | 41.29M | 70.17M | 80.28M | 86.17M | 71.71M | 55.64M |
R&D % of Revenue | 217.26% | 217.16% | 316.74% | - | - | - | - | - | 75.58% |
Other Operating Expenses | 0 | 0 | -40.19M | -41.29M | 0 | 0 | -86.17M | 0 | 0 |
Operating Income | -18.7M▲ 0% | -29.82M▼ 59.4% | -40.53M▼ 35.9% | -57.92M▼ 42.9% | -96.61M▼ 66.8% | -110.87M▼ 14.8% | -140.44M▼ 26.7% | -188M▼ 33.9% | -171.84M▲ 8.6% |
Operating Margin % | -222.84% | -184.91% | -319.41% | - | - | - | - | - | -233.42% |
Operating Income Growth % | 16.27% | -59.42% | -35.93% | -42.9% | -66.8% | -14.76% | -26.67% | -33.86% | 8.59% |
EBITDA | -18.52M | -29.44M | -40.02M | -57.39M | -96.05M | -110.15M | -139.63M | -187.05M | -170.38M |
EBITDA Margin % | -220.69% | -182.56% | -315.37% | - | - | - | - | - | -231.45% |
EBITDA Growth % | 16.92% | -58.93% | -35.93% | -43.39% | -67.37% | -14.68% | -26.76% | -33.97% | 8.91% |
D&A (Non-Cash Add-back) | 180K | 378K | 512K | 537K | 564K | 718K | 816K | 941K | 1.45M |
EBIT | -18.7M | -29.82M | -40.53M | -57.92M | -81.31M | -95.09M | -135.1M | -174.27M | -171.84M |
Net Interest Income | 82K | 1.4M | 1.83M | 903K | 1.09M | 2.23M | 3.9M | 650K | -10.66M |
Interest Income | 82K | 1.4M | 1.83M | 903K | 1.09M | 2.23M | 3.9M | 6.43M | 8.68M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5.79M | 19.34M |
Other Income/Expense | 2.9M | 9.13M | 11.54M | 11.68M | 14.27M | 17.96M | 5.35M | 7.94M | 420K |
Pretax Income | -15.8M▲ 0% | -20.69M▼ 30.9% | -28.99M▼ 40.1% | -46.24M▼ 59.5% | -82.34M▼ 78.1% | -92.91M▼ 12.8% | -135.1M▼ 45.4% | -180.05M▼ 33.3% | -171.42M▲ 4.8% |
Pretax Margin % | -188.29% | -128.31% | -228.46% | - | - | - | - | - | -232.85% |
Income Tax | 0 | 124K | 124K | 0 | 0 | 0 | -8.45M | 3.39M | -7.13M |
Effective Tax Rate % | 0% | -0.6% | -0.43% | 0% | 0% | 0% | 6.26% | -1.88% | 4.16% |
Net Income | -15.8M▲ 0% | -20.82M▼ 31.7% | -29.12M▼ 39.9% | -46.24M▼ 58.8% | -82.34M▼ 78.1% | -92.91M▼ 12.8% | -126.64M▼ 36.3% | -183.44M▼ 44.9% | -164.29M▲ 10.4% |
Net Margin % | -188.29% | -129.08% | -229.44% | - | - | - | - | - | -223.16% |
Net Income Growth % | 15.04% | -31.71% | -39.87% | -58.83% | -78.05% | -12.83% | -36.31% | -44.85% | 10.44% |
Net Income (Continuing) | -15.8M | -20.82M | -29.12M | -46.24M | -82.34M | -92.91M | -126.64M | -183.44M | -164.29M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.53▲ 0% | -1.38▲ 9.8% | -1.64▼ 18.8% | -2.33▼ 42.1% | -3.36▼ 44.2% | -3.33▲ 0.9% | -3.44▼ 3.3% | -3.69▼ 7.3% | -3.23▲ 12.5% |
EPS Growth % | 20.31% | 9.8% | -18.84% | -42.07% | -44.21% | 0.89% | -3.3% | -7.27% | 12.47% |
EPS (Basic) | -1.53 | -1.38 | -1.64 | -2.33 | -3.36 | -3.33 | -3.44 | -3.69 | -3.23 |
Diluted Shares Outstanding | 10.32M | 15.08M | 17.75M | 19.09M | 24.47M | 27.89M | 36.79M | 49.65M | 50.9M |
Basic Shares Outstanding | 10.32M | 15.08M | 17.75M | 19.09M | 24.47M | 27.89M | 36.79M | 49.65M | 50.9M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
KALV Balance Sheet
KalVista Pharmaceuticals, Inc. (KALV) balance sheet — assets, liabilities & shareholders' equity
| Metric | Apr'18 | Apr'19 | Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | Apr'25 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 59.38M | 115.55M | 88.7M | 264.26M | 193.65M | 172.33M | 225.69M | 241.69M | 320.15M |
Cash & Short-Term Investments | 51.05M | 100.81M | 67.71M | 248.93M | 166.2M | 149.38M | 210.4M | 187.65M | 300.21M |
Cash Only | 51.05M | 32.01M | 15.79M | 50.59M | 30.73M | 56.24M | 31.79M | 98.64M | 229.34M |
Short-Term Investments | 0 | 68.81M | 51.92M | 198.34M | 135.47M | 93.14M | 178.61M | 89M | 70.87M |
Accounts Receivable | 6.83M | 11.31M | 16.53M | 11.72M | 16.81M | 18.64M | 10.87M | 15.14M | 11.3M |
Days Sales Outstanding | 297.17 | 256.09 | 475.36 | - | - | - | - | - | 56.04 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.43M |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | 205.96 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19.21M | 0 |
Total Non-Current Assets | 2.01M | 2.59M | 3.83M | 7.75M | 10.23M | 10.88M | 9.71M | 9.08M | 15.23M |
Property, Plant & Equipment | 1.84M | 2.41M | 3.65M | 7.55M | 10.04M | 10.77M | 9.15M | 1.99M | 12.86M |
Fixed Asset Turnover | 4.57x | 6.68x | 3.47x | - | - | - | - | - | 5.72x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 173K | 173K | 178K | 200K | 193K | 106K | 567K | 7.09M | 2.37M |
Total Assets | 61.39M▲ 0% | 118.13M▲ 92.4% | 92.53M▼ 21.7% | 272.01M▲ 194.0% | 203.88M▼ 25.0% | 183.2M▼ 10.1% | 235.4M▲ 28.5% | 250.77M▲ 6.5% | 335.38M▲ 33.7% |
Asset Turnover | 0.14x | 0.14x | 0.14x | - | - | - | - | - | 0.22x |
Asset Growth % | 78.74% | 92.43% | -21.67% | 193.98% | -25.05% | -10.14% | 28.49% | 6.53% | 33.74% |
Total Current Liabilities | 23.22M | 18.05M | 7.72M | 9.77M | 11.58M | 15.03M | 22.81M | 45.17M | 57.35M |
Accounts Payable | 1.43M | 2.86M | 1.68M | 1.98M | 3.64M | 4.82M | 9.11M | 4.88M | 8.27M |
Days Payables Outstanding | 28.68K | 29.81K | 15.23 | 17.51 | - | - | 38.58 | - | 496.76 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 18.48M | 9.54M | 0 | 0 | 0 | 0 | 0 | 11M | 0 |
Other Current Liabilities | 0 | 0 | 0 | 3.51M | 4.17M | 4.21M | 6.69M | 0 | 36.8M |
Current Ratio | 2.56x | 6.40x | 11.49x | 27.04x | 16.73x | 11.46x | 9.90x | 5.35x | 5.58x |
Quick Ratio | 2.56x | 6.40x | 11.49x | 27.04x | 16.73x | 11.46x | 9.90x | 5.35x | 5.52x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | -234.76 |
Total Non-Current Liabilities | 10.92M | 3.34M | 1.06M | 5.05M | 7.21M | 7.14M | 6.01M | 110.21M | 280.73M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 139.23M |
Capital Lease Obligations | 58K | 0 | 1.06M | 5.05M | 7.21M | 7.14M | 6.01M | 4.33M | 10.73M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 10.86M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 119.06M |
Total Liabilities | 34.14M | 21.39M | 8.78M | 14.82M | 18.79M | 22.18M | 28.82M | 155.38M | 338.09M |
Total Debt | 279K | 54K | 1.65M | 5.91M | 8.19M | 8.23M | 7.32M | 6.31M | 151.57M |
Net Debt | -50.78M | -31.95M | -14.14M | -44.68M | -22.54M | -48.01M | -24.47M | -92.34M | -77.77M |
Debt / Equity | 0.01x | 0.00x | 0.02x | 0.02x | 0.04x | 0.05x | 0.04x | 0.07x | - |
Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
Interest Coverage | - | - | - | - | - | - | - | -30.12x | -8.88x |
Total Equity | 27.25M▲ 0% | 96.74M▲ 255.0% | 83.75M▼ 13.4% | 257.19M▲ 207.1% | 185.09M▼ 28.0% | 161.03M▼ 13.0% | 206.58M▲ 28.3% | 95.39M▼ 53.8% | -2.71M▼ 102.8% |
Equity Growth % | -13% | 254.96% | -13.42% | 207.09% | -28.03% | -13% | 28.29% | -53.82% | -102.84% |
Book Value per Share | 2.64 | 6.41 | 4.72 | 13.47 | 7.56 | 5.77 | 5.62 | 1.92 | -0.05 |
Total Shareholders' Equity | 27.25M | 96.74M | 83.75M | 257.19M | 185.09M | 161.03M | 206.58M | 95.39M | -2.71M |
Common Stock | 11K | 17K | 18K | 24K | 25K | 34K | 42K | 50K | 51K |
Retained Earnings | -71.66M | -92.48M | -121.59M | -167.84M | -250.18M | -343.08M | -469.73M | -653.17M | -762.69M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -1.11M | -1.93M | -1.88M | -1.43M | -3.86M | -3.06M | -3.49M | -5.21M | -7.13M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KALV Cash Flow Statement
KalVista Pharmaceuticals, Inc. (KALV) cash flow — operating, investing & free cash flow history
| Metric | Apr'18 | Apr'19 | Apr'20 | Apr'21 | Apr'22 | Apr'23 | Apr'24 | Apr'25 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 10.56M | -36.37M | -44.82M | -30.17M | -78.13M | -75.26M | -89.23M | -152.91M | -81.62M |
Operating CF Margin % | 125.78% | -225.49% | -353.16% | - | - | - | - | - | -110.87% |
Operating CF Growth % | 144.51% | -444.43% | -23.24% | 32.68% | -158.97% | 3.68% | -18.56% | -71.36% | 46.62% |
Net Income | -15.8M | -20.82M | -29.12M | -46.24M | -82.34M | -92.91M | -126.64M | -183.44M | -164.29M |
Depreciation & Amortization | 180K | 378K | 512K | 537K | 743K | 718K | 816K | 941K | 1.45M |
Stock-Based Compensation | 1.06M | 2.97M | 4.45M | 7.12M | 0 | 9.92M | 21.91M | 12.29M | 0 |
Deferred Taxes | 0 | 0 | -33K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -651K | -103K | 13K | 72K | 15.78M | -407K | -485K | 2.27M | 80.26M |
Working Capital Changes | 25.77M | -18.79M | -20.64M | 8.35M | -12.32M | 7.41M | 15.17M | 15.04M | 954K |
Change in Receivables | -3.94M | -4.88M | -5.78M | 7.46M | -5.2M | -2.32M | 8.18M | -3.62M | -7.4M |
Change in Inventory | 0 | 4.88M | 5.78M | 0 | 0 | 0 | 0 | 0 | -3.43M |
Change in Payables | 217K | 1.53M | -1M | 150K | 1.69M | 1.11M | 4.32M | -4.97M | 4.19M |
Cash from Investing | -1.43M | -69.42M | 16.75M | -147.65M | 57.86M | 41.41M | -84.72M | 91.02M | 18.68M |
Capital Expenditures | -1.43M | -1.08M | -220K | -82K | -931K | -1.2M | -42K | -929K | -1.9M |
CapEx % of Revenue | 17% | 6.7% | 1.73% | - | - | - | - | - | 2.58% |
Acquisitions | 0 | 69.42M | -16.75M | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | -1.43M | -69.42M | 16.75M | 0 | 0 | 0 | -401K | 0 | 0 |
Cash from Financing | 8.99M | 87.94M | 11.58M | 212.12M | 1.58M | 58.12M | 150.71M | 159.73M | 162.64M |
Debt Issued (Net) | -151K | -209K | -54K | 0 | 0 | 0 | 0 | 98.04M | 160.72M |
Equity Issued (Net) | 9.14M | 87.91M | 11.42M | 210.58M | 1.58M | 56.58M | 96.94M | 61.69M | 1.92M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 242K | 216K | 1.53M | 0 | 1.53M | 53.77M | 0 | 0 |
Net Change in Cash | 20.11M▲ 0% | -19.05M▼ 194.7% | -16.22M▲ 14.9% | 34.8M▲ 314.6% | -19.86M▼ 157.1% | 25.51M▲ 228.4% | -24.45M▼ 195.9% | 99.83M▲ 508.3% | 97.73M▼ 2.1% |
Free Cash Flow | 9.13M▲ 0% | -37.45M▼ 510.1% | -45.04M▼ 20.3% | -30.25M▲ 32.8% | -79.06M▼ 161.3% | -76.46M▲ 3.3% | -89.67M▼ 17.3% | -153.34M▼ 71.0% | -83.33M▲ 45.7% |
FCF Margin % | 108.78% | -232.19% | -354.89% | - | - | - | - | - | -113.19% |
FCF Growth % | 138.37% | -510.1% | -20.27% | 32.82% | -161.35% | 3.3% | -17.29% | -71% | 45.66% |
FCF per Share | 0.88 | -2.48 | -2.54 | -1.58 | -3.23 | -2.74 | -2.44 | -3.09 | -1.64 |
FCF Conversion (FCF/Net Income) | -0.67x | 1.75x | 1.54x | 0.65x | 0.95x | 0.81x | 0.70x | 0.83x | 0.50x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KALV Key Ratios
KalVista Pharmaceuticals, Inc. (KALV) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -70.44% | -53.96% | -33.58% | -32.26% | -27.13% | -37.23% | -53.69% | -68.9% | -121.5% | -354.52% |
Return on Invested Capital (ROIC) | -710.23% | - | -108.4% | -45.24% | -30.8% | -38.64% | -60.35% | -71.38% | -152.29% | - |
Gross Margin | 99.16% | 99.78% | 99.78% | -216.74% | - | - | - | - | - | 91.75% |
Net Margin | -1236.9% | -188.29% | -129.08% | -229.44% | - | - | - | - | - | -223.16% |
Debt / Equity | - | 0.01x | 0.00x | 0.02x | 0.02x | 0.04x | 0.05x | 0.04x | 0.07x | - |
Interest Coverage | - | - | - | - | - | - | - | - | -30.12x | -8.88x |
FCF Conversion | 1.28x | -0.67x | 1.75x | 1.54x | 0.65x | 0.95x | 0.81x | 0.70x | 0.83x | 0.50x |
Revenue Growth | -29.49% | 458.11% | 92.13% | -21.31% | -100% | - | - | - | - | - |
Related:KALV Dividend History·KALV Revenue History·KALV Price History·KALV P/E History·KALV Financial Ratios·KALV Institutional Holders
KALV SEC Filings & Documents
KalVista Pharmaceuticals, Inc. (KALV) SEC filings — annual & quarterly reports (10-K, 10-Q)
KALV Frequently Asked Questions
KalVista Pharmaceuticals, Inc. (KALV) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
KalVista Pharmaceuticals, Inc. (KALV) reported $115.9M in revenue for fiscal year 2026. This represents a 7436% increase from $1.5M in 2013.
KalVista Pharmaceuticals, Inc. (KALV) grew revenue by 0.0% over the past year. Growth has been modest.
KalVista Pharmaceuticals, Inc. (KALV) reported a net loss of $138.4M for fiscal year 2026.
Dividend & Returns
KalVista Pharmaceuticals, Inc. (KALV) has a return on equity (ROE) of -354.5%. Negative ROE indicates the company is unprofitable.
KalVista Pharmaceuticals, Inc. (KALV) had negative free cash flow of $23.8M in fiscal year 2026, likely due to heavy capital investments.